AW
ANIP icon

Ankerstar Wealth’s ANI Pharmaceuticals ANIP Stock Holding History

Ankerstar Wealth’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$497 Hold
6
– – ﹤0.01% 661
2026
Q1 		$461 Buy
6
+1
+20% +$78 ﹤0.01% 636
2025
Q4 		$395 Buy
+5
New +$433 ﹤0.01% 715

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ankerstar Wealth's ANIP Position: Q2 2026 in Review

Ankerstar Wealth held its ANI Pharmaceuticals (ANIP) position steady in Q2 2026 at 6 shares worth $497. The position accounts for ﹤0.01% of the portfolio, ranked #661.

Ankerstar Wealth first reported a position in ANIP in Q4 2025 and has held it in 3 quarters since. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Ankerstar Wealth held 6 shares of ANI Pharmaceuticals worth $497 as of Q2 2026.
  • Ankerstar Wealth left its ANI Pharmaceuticals share count unchanged in Q2 2026.
  • ANI Pharmaceuticals made up ﹤0.01% of Ankerstar Wealth's portfolio in Q2 2026, its #661 holding.
  • Ankerstar Wealth first reported a position in ANI Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Ankerstar Wealth's 13F filing for Q2 2026, filed 13 Aug 2026.